NCT07232641 Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic
| NCT ID | NCT07232641 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston University |
| Condition | Substance Use Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 185,810 participants |
| Start Date | 2026-06-30 |
| Primary Completion | 2029-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 185,810 participants in total. It began in 2026-06-30 with a primary completion date of 2029-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
"Gold-standard" medications for opioid use disorder (MOUD) treatment combines FDA-approved medications, primarily methadone and buprenorphine, with behavioral therapies to provide "whole-patient" treatment. Prior to the pandemic, methadone and buprenorphine were subject to greater federal regulations than medications for other substance use disorders, including medication for alcohol use disorder (MAUD), which created barriers to MOUD initiation and retention. These barriers were exacerbated by physical distancing and diminished clinic capacities during the COVID-19 pandemic. To prevent healthcare disruption and expand access to MOUD treatment during the public health emergency, federal and state authorities implemented several MOUD policy changes during the pandemic to reduce barriers to MOUD initiation and retention, which subsequently became permanent. This study is an evaluation of the impacts of these policies on treatment use, retention, and patient outcomes pre- and post-MOUD policy implementation.
Eligibility Criteria
Inclusion Criteria: * Substance use disorder (alcohol and/or opioid) documented in the Veteran's Health Administration Corporate Data Warehouse (CDW) Exclusion Criteria: * None
Contact & Investigator
Nicholas Livingston, PhD
PRINCIPAL INVESTIGATOR
BUCA School of Medicine, Psychiatry and VA Medical Center
Frequently Asked Questions
Who can join the NCT07232641 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Substance Use Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07232641 currently recruiting?
Yes, NCT07232641 is actively recruiting participants. Contact the research team at livingn@bu.edu for enrollment information.
Where is the NCT07232641 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07232641 clinical trial?
NCT07232641 is sponsored by Boston University. The principal investigator is Nicholas Livingston, PhD at BUCA School of Medicine, Psychiatry and VA Medical Center. The trial plans to enroll 185,810 participants.